Cutibacterium acnes (C. acnes) is involved in the pathogenesis of acne by inducing inflammation and biofilm formation, along with other virulence factors. A Camellia sinensis (C. sinensis) callus lysate is proposed to reduce these effects. The aim of the present work is to study the anti-inflammatory properties of a callus extract from C. sinensis on C. acnes-stimulated human keratinocytes and the quorum-quenching activities. Keratinocytes were stimulated with thermo-inactivated pathogenic C. acnes and were treated with the herbal lysate (0.25% w/w) to evaluate its anti-inflammatory effect. C. acnes biofilm was developed in vitro and treated with 2.5 and 5% w/w of the lysate to evaluate quorum sensing and the lipase activity. The results showed that the lysate was able to reduce the production of interleukin-6 (IL-6), interleukin-8 (IL-8), tumor necrosis factor-α (TNF-α), and C-X-C motif chemokine ligand 1 (CXCL1), and decrease the nuclear translocation of nuclear factor kappa light chain enhancer of activated B cells (NF-κB). The lysate did not show bactericidal activity but showed diminished biofilm formation, the lipase activity, and the production of autoinducer 2 (AI-2), a member of a family of signaling molecules used in quorum sensing. Therefore, the proposed callus lysate could have the potential to reduce acne-related symptoms without the eradication of C. acnes, which is part of the natural skin microbiome.

Acne vulgaris remains a common condition, with current topical therapies often limited by suboptimal efficacy and tolerability. This study evaluated the efficacy and safety of two novel 1% hydrogen peroxide (H₂O₂) formulations, a cream-gel for facial and a sprayable lotion for truncal mild-to-moderate acne. 42 participants presenting facial acne and 41 with truncal acne were treated twice daily for 8 weeks. Efficacy was assessed using the Investigator’s Global Assessment (IGA), the Spanish Acne Severity Scale (EGAE), and lesion counts. After 56 days, facial acne severity improved significantly (IGA −26%, p = 0.01; EGAE −31%, p = 0.01), with reductions in papules (−45%, p = 0.017), porphyrin count (−27%, p = 0.04), sebum production (−75%, p = 0.005), erythema (−35%, p = 0.0001), and desquamation (−22%, p = 0.02). Truncal acne severity also improved significantly (IGA −32%, p = 0.001; EGAE −45%, p = 0.001), with reductions in inflammatory lesions (−60%, p = 0.001), porphyrin size and count (−55% and −48%, both p = 0.001), erythema (−7%, p = 0.005), and desquamation (−27%, p = 0.001). Both formulations were accepted by the users, with minimal local irritation and high patient satisfaction. Topical 1% H₂O₂ formulations demonstrated significant and well-tolerated efficacy in both facial and truncal acne, supporting their potential as safe and patient-friendly options for managing mild-to-moderate acne.

Acne vulgaris remains a common condition, with current topical therapies often limited by suboptimal efficacy and tolerability. This study evaluated the efficacy and safety of two novel 1% hydrogen peroxide (H₂O₂) formulations, a cream-gel for facial and a sprayable lotion for truncal mild to moderate acne. 42 participants presenting facial acne and 41 with truncal acne were treated twice daily for 8 weeks. Efficacy was assessed using the Investigator’s Global Assessment (IGA), the Spanish Acne Severity Scale (EGAE), and lesion counts. After 56 days, facial acne severity improved significantly (IGA −26%, p=0.01; EGAE −31%, p=0.01), with reductions in papules (−45%, p=0.017), porphyrin count (−27%, p=0.04), sebum production (−75%, p=0.005), erythema (−35%, p=0.0001), and desquamation (−22%, p=0.02). Truncal acne severity also improved sig-nificantly (IGA −32%, p=0.001; EGAE −45%, p=0.001), with reductions in inflammatory lesions (−60%, p=0.001), porphyrin size and count (-55% and −48%, both p=0.001), ery-thema (−7%, p=0.005), and desquamation (−27%, p=0.001). Both formulations were ac-cepted by the users, with minimal local irritation and high patient satisfaction. Topical 1% H₂O₂ formulations demonstrated significant and well-tolerated efficacy in both fa-cial and truncal acne, supporting their potential as safe and patient-friendly options for managing mild to moderate acne.